Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial
Background The prevalent raise of type 2 diabetes (T2D) around the globe, are creating higher risk for cardiovascular diseases (CVDs) and increasing strain on each country’s health care budget in the world. Microalbuminuria has appeared as a key parameter in diabetic patients. Microalbuminuria is al...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes and metabolic disorders 2017-06, Vol.16 (1), p.23-23, Article 23 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Journal of diabetes and metabolic disorders |
| container_volume | 16 |
| creator | Ebrahimi, Zarin sadat Nasli-Esfahani, Ensieh Nadjarzade, Azadeh Mozaffari-khosravi, Hassan |
| description | Background
The prevalent raise of type 2 diabetes (T2D) around the globe, are creating higher risk for cardiovascular diseases (CVDs) and increasing strain on each country’s health care budget in the world. Microalbuminuria has appeared as a key parameter in diabetic patients. Microalbuminuria is also related to increased cardiovascular morbidity in people who are non-obese diabetic. Some studies have suggested that consumption of symbiotic foods might help improve the metabolic profile, inflammatory factors and biomarkers of oxidative stress. The aim of trial was to determine the effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in non-obese T2D.
Methods
In this randomized, double-blind, clinically controlled trial, 70 patients with T2D (28 females, 42 males) were randomly divided into two groups (
n
= 35 for each group). The symbiotic group (SG) consumed 500 mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate and the placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate for 9 weeks. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c), blood lipid profiles, 24-h dietary recalls, and anthropometric measurements were measured at the baseline and at the end of trial. SPSS software, version 16 was used to test the data and the results were expressed as mean ± standard deviation. Paired samples T-Test were used to compare continuous variables within groups. Comparison between different groups was performed through two independent samples T-Test. In the absence of normal distribution, the comparison between the groups was made using non-parametric Wilcoxon on signed ranks and Mann–Whitney tests. P values |
| doi_str_mv | 10.1186/s40200-017-0304-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5457616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A507275165</galeid><sourcerecordid>A507275165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-56b5c16b9c74cde45aa8b2a5239fe9e76b51896adda1ad551ab0bed93eba4dcf3</originalsourceid><addsrcrecordid>eNp1kttqFTEUhgdRbKl9AG8kIIgXnZrMTObghVBKPUDBG70OOazZOyWTjEmmsn0tX9A17Fp3RScDmbC-9Q8r_18Uzxk9Z6xv36SGVpSWlHUlrWlT9o-K46rirGx5zx4ffB8VpyndUHy6ru9Z-7Q4qnreD4zWx8XPq3EEnUkYSdpNyoZsNUnLPDuYwGeZbfAE343baZiwpoPPMbgz4uxsDZljGK2DRKQ3BOsxSKeWyfolWkmsJzNKoFAi323eEh98GRQkIHk3A6mIsVJBhvSWSBJRI0z2B5gzYsKiHJTKWY8njZvV0pGMqu5Z8WSULsHp3X5SfH1_9eXyY3n9-cOny4vrUvO2zyVvFdesVYPuGm2g4VL2qpK8qocRBuiwzPqhlcZIJg3nTCqqwAw1KNkYPdYnxbu97ryoCYzGMaJ0Yo52knEngrTiYcXbrdiEW8Eb3rWsRYHXdwIxfFsgZTHZpME56SEsSbCBdugKG2pEX_6F3oQlehxvpTjvm4HxP9RGOhDWjwH_q1dRccFpV3WctSt1_g8Kl1kdDB5Wxx42vDpo2IJ0eZuCW1bz00OQ7UH0OaUI4_1lMCrWVIp9KgWmUqypFD32vDi8xfuO3xlEoNoDCUt-A_Fg9P-q_gIWOfAa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1905584915</pqid></control><display><type>article</type><title>Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial</title><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ebrahimi, Zarin sadat ; Nasli-Esfahani, Ensieh ; Nadjarzade, Azadeh ; Mozaffari-khosravi, Hassan</creator><creatorcontrib>Ebrahimi, Zarin sadat ; Nasli-Esfahani, Ensieh ; Nadjarzade, Azadeh ; Mozaffari-khosravi, Hassan</creatorcontrib><description>Background
The prevalent raise of type 2 diabetes (T2D) around the globe, are creating higher risk for cardiovascular diseases (CVDs) and increasing strain on each country’s health care budget in the world. Microalbuminuria has appeared as a key parameter in diabetic patients. Microalbuminuria is also related to increased cardiovascular morbidity in people who are non-obese diabetic. Some studies have suggested that consumption of symbiotic foods might help improve the metabolic profile, inflammatory factors and biomarkers of oxidative stress. The aim of trial was to determine the effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in non-obese T2D.
Methods
In this randomized, double-blind, clinically controlled trial, 70 patients with T2D (28 females, 42 males) were randomly divided into two groups (
n
= 35 for each group). The symbiotic group (SG) consumed 500 mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate and the placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate for 9 weeks. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c), blood lipid profiles, 24-h dietary recalls, and anthropometric measurements were measured at the baseline and at the end of trial. SPSS software, version 16 was used to test the data and the results were expressed as mean ± standard deviation. Paired samples T-Test were used to compare continuous variables within groups. Comparison between different groups was performed through two independent samples T-Test. In the absence of normal distribution, the comparison between the groups was made using non-parametric Wilcoxon on signed ranks and Mann–Whitney tests. P values <0.05 was considered significant.
Results
Symbiotic supplementation decreased significantly, FBG (
P
= 0.05) and HbA1c (P < 0.01). There were no significant differences in lipid profiles within and between the groups at the end of study (P > 0.05). Microalbuminuria (P < 0.05) and HbA1c (P < 0.05) are increased significantly in PG at the end of the study. Furthermore, the mean changes of microalbuminuria and HbA1c experienced significant between the two groups. There was significant reduction in urea between two groups from baseline (
P
= 0.051). No significant changes in baseline were shown in creatinine among the two groups or within either groups (P > 0.05).
Conclusion
The consumption of 500 mg/d symbiotic supplementation for 9 weeks could improve the HbA1c, BMI and Microalbuminuria in T2D. Although, No effect has been indicated on FBS, lipid profiles, urea and creatinine.
Trial Registration
The trial has been registered in the Iranian Registry of Clinical Trials
IRCT2015072223284N1
, identifier. Registered 21 May 2016 “retrospectively registered”.</description><identifier>ISSN: 2251-6581</identifier><identifier>EISSN: 2251-6581</identifier><identifier>DOI: 10.1186/s40200-017-0304-8</identifier><identifier>PMID: 28589103</identifier><language>eng</language><publisher>London: BioMed Central</publisher><subject>Blood glucose ; Cardiovascular diseases ; Care and treatment ; Clinical trials ; Complications and side effects ; Diabetes ; Diet ; Double-blind studies ; Endocrinology ; Health aspects ; Hormones ; Inflammation ; Insulin resistance ; Lipids ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolism ; Mortality ; Nutrition research ; Oxidative stress ; Peptides ; Permeability ; Prebiotics ; Probiotics ; Research Article ; Risk factors ; Rodents ; Studies ; Type 2 diabetes</subject><ispartof>Journal of diabetes and metabolic disorders, 2017-06, Vol.16 (1), p.23-23, Article 23</ispartof><rights>The Author(s). 2017</rights><rights>COPYRIGHT 2017 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-56b5c16b9c74cde45aa8b2a5239fe9e76b51896adda1ad551ab0bed93eba4dcf3</citedby><cites>FETCH-LOGICAL-c568t-56b5c16b9c74cde45aa8b2a5239fe9e76b51896adda1ad551ab0bed93eba4dcf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457616/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457616/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28589103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebrahimi, Zarin sadat</creatorcontrib><creatorcontrib>Nasli-Esfahani, Ensieh</creatorcontrib><creatorcontrib>Nadjarzade, Azadeh</creatorcontrib><creatorcontrib>Mozaffari-khosravi, Hassan</creatorcontrib><title>Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial</title><title>Journal of diabetes and metabolic disorders</title><addtitle>J Diabetes Metab Disord</addtitle><addtitle>J Diabetes Metab Disord</addtitle><description>Background
The prevalent raise of type 2 diabetes (T2D) around the globe, are creating higher risk for cardiovascular diseases (CVDs) and increasing strain on each country’s health care budget in the world. Microalbuminuria has appeared as a key parameter in diabetic patients. Microalbuminuria is also related to increased cardiovascular morbidity in people who are non-obese diabetic. Some studies have suggested that consumption of symbiotic foods might help improve the metabolic profile, inflammatory factors and biomarkers of oxidative stress. The aim of trial was to determine the effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in non-obese T2D.
Methods
In this randomized, double-blind, clinically controlled trial, 70 patients with T2D (28 females, 42 males) were randomly divided into two groups (
n
= 35 for each group). The symbiotic group (SG) consumed 500 mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate and the placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate for 9 weeks. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c), blood lipid profiles, 24-h dietary recalls, and anthropometric measurements were measured at the baseline and at the end of trial. SPSS software, version 16 was used to test the data and the results were expressed as mean ± standard deviation. Paired samples T-Test were used to compare continuous variables within groups. Comparison between different groups was performed through two independent samples T-Test. In the absence of normal distribution, the comparison between the groups was made using non-parametric Wilcoxon on signed ranks and Mann–Whitney tests. P values <0.05 was considered significant.
Results
Symbiotic supplementation decreased significantly, FBG (
P
= 0.05) and HbA1c (P < 0.01). There were no significant differences in lipid profiles within and between the groups at the end of study (P > 0.05). Microalbuminuria (P < 0.05) and HbA1c (P < 0.05) are increased significantly in PG at the end of the study. Furthermore, the mean changes of microalbuminuria and HbA1c experienced significant between the two groups. There was significant reduction in urea between two groups from baseline (
P
= 0.051). No significant changes in baseline were shown in creatinine among the two groups or within either groups (P > 0.05).
Conclusion
The consumption of 500 mg/d symbiotic supplementation for 9 weeks could improve the HbA1c, BMI and Microalbuminuria in T2D. Although, No effect has been indicated on FBS, lipid profiles, urea and creatinine.
Trial Registration
The trial has been registered in the Iranian Registry of Clinical Trials
IRCT2015072223284N1
, identifier. Registered 21 May 2016 “retrospectively registered”.</description><subject>Blood glucose</subject><subject>Cardiovascular diseases</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Diet</subject><subject>Double-blind studies</subject><subject>Endocrinology</subject><subject>Health aspects</subject><subject>Hormones</subject><subject>Inflammation</subject><subject>Insulin resistance</subject><subject>Lipids</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metabolism</subject><subject>Mortality</subject><subject>Nutrition research</subject><subject>Oxidative stress</subject><subject>Peptides</subject><subject>Permeability</subject><subject>Prebiotics</subject><subject>Probiotics</subject><subject>Research Article</subject><subject>Risk factors</subject><subject>Rodents</subject><subject>Studies</subject><subject>Type 2 diabetes</subject><issn>2251-6581</issn><issn>2251-6581</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kttqFTEUhgdRbKl9AG8kIIgXnZrMTObghVBKPUDBG70OOazZOyWTjEmmsn0tX9A17Fp3RScDmbC-9Q8r_18Uzxk9Z6xv36SGVpSWlHUlrWlT9o-K46rirGx5zx4ffB8VpyndUHy6ru9Z-7Q4qnreD4zWx8XPq3EEnUkYSdpNyoZsNUnLPDuYwGeZbfAE343baZiwpoPPMbgz4uxsDZljGK2DRKQ3BOsxSKeWyfolWkmsJzNKoFAi323eEh98GRQkIHk3A6mIsVJBhvSWSBJRI0z2B5gzYsKiHJTKWY8njZvV0pGMqu5Z8WSULsHp3X5SfH1_9eXyY3n9-cOny4vrUvO2zyVvFdesVYPuGm2g4VL2qpK8qocRBuiwzPqhlcZIJg3nTCqqwAw1KNkYPdYnxbu97ryoCYzGMaJ0Yo52knEngrTiYcXbrdiEW8Eb3rWsRYHXdwIxfFsgZTHZpME56SEsSbCBdugKG2pEX_6F3oQlehxvpTjvm4HxP9RGOhDWjwH_q1dRccFpV3WctSt1_g8Kl1kdDB5Wxx42vDpo2IJ0eZuCW1bz00OQ7UH0OaUI4_1lMCrWVIp9KgWmUqypFD32vDi8xfuO3xlEoNoDCUt-A_Fg9P-q_gIWOfAa</recordid><startdate>20170602</startdate><enddate>20170602</enddate><creator>Ebrahimi, Zarin sadat</creator><creator>Nasli-Esfahani, Ensieh</creator><creator>Nadjarzade, Azadeh</creator><creator>Mozaffari-khosravi, Hassan</creator><general>BioMed Central</general><general>BioMed Central Ltd</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170602</creationdate><title>Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial</title><author>Ebrahimi, Zarin sadat ; Nasli-Esfahani, Ensieh ; Nadjarzade, Azadeh ; Mozaffari-khosravi, Hassan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-56b5c16b9c74cde45aa8b2a5239fe9e76b51896adda1ad551ab0bed93eba4dcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Blood glucose</topic><topic>Cardiovascular diseases</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Diet</topic><topic>Double-blind studies</topic><topic>Endocrinology</topic><topic>Health aspects</topic><topic>Hormones</topic><topic>Inflammation</topic><topic>Insulin resistance</topic><topic>Lipids</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metabolism</topic><topic>Mortality</topic><topic>Nutrition research</topic><topic>Oxidative stress</topic><topic>Peptides</topic><topic>Permeability</topic><topic>Prebiotics</topic><topic>Probiotics</topic><topic>Research Article</topic><topic>Risk factors</topic><topic>Rodents</topic><topic>Studies</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebrahimi, Zarin sadat</creatorcontrib><creatorcontrib>Nasli-Esfahani, Ensieh</creatorcontrib><creatorcontrib>Nadjarzade, Azadeh</creatorcontrib><creatorcontrib>Mozaffari-khosravi, Hassan</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes and metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebrahimi, Zarin sadat</au><au>Nasli-Esfahani, Ensieh</au><au>Nadjarzade, Azadeh</au><au>Mozaffari-khosravi, Hassan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial</atitle><jtitle>Journal of diabetes and metabolic disorders</jtitle><stitle>J Diabetes Metab Disord</stitle><addtitle>J Diabetes Metab Disord</addtitle><date>2017-06-02</date><risdate>2017</risdate><volume>16</volume><issue>1</issue><spage>23</spage><epage>23</epage><pages>23-23</pages><artnum>23</artnum><issn>2251-6581</issn><eissn>2251-6581</eissn><abstract>Background
The prevalent raise of type 2 diabetes (T2D) around the globe, are creating higher risk for cardiovascular diseases (CVDs) and increasing strain on each country’s health care budget in the world. Microalbuminuria has appeared as a key parameter in diabetic patients. Microalbuminuria is also related to increased cardiovascular morbidity in people who are non-obese diabetic. Some studies have suggested that consumption of symbiotic foods might help improve the metabolic profile, inflammatory factors and biomarkers of oxidative stress. The aim of trial was to determine the effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in non-obese T2D.
Methods
In this randomized, double-blind, clinically controlled trial, 70 patients with T2D (28 females, 42 males) were randomly divided into two groups (
n
= 35 for each group). The symbiotic group (SG) consumed 500 mg/d of symbiotic supplementations containing probiotics (Lactobacillus family, Bifidobacterium family, Streptococus thermophilus), Prebiotics (Fructo oligosaccharide) and B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate and the placebo group (PG) consumed capsules filled with row starch and also B group vitamins (1 mg), lactose (0.5 mg), malt-dextrin, magnesium saturate for 9 weeks. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c), blood lipid profiles, 24-h dietary recalls, and anthropometric measurements were measured at the baseline and at the end of trial. SPSS software, version 16 was used to test the data and the results were expressed as mean ± standard deviation. Paired samples T-Test were used to compare continuous variables within groups. Comparison between different groups was performed through two independent samples T-Test. In the absence of normal distribution, the comparison between the groups was made using non-parametric Wilcoxon on signed ranks and Mann–Whitney tests. P values <0.05 was considered significant.
Results
Symbiotic supplementation decreased significantly, FBG (
P
= 0.05) and HbA1c (P < 0.01). There were no significant differences in lipid profiles within and between the groups at the end of study (P > 0.05). Microalbuminuria (P < 0.05) and HbA1c (P < 0.05) are increased significantly in PG at the end of the study. Furthermore, the mean changes of microalbuminuria and HbA1c experienced significant between the two groups. There was significant reduction in urea between two groups from baseline (
P
= 0.051). No significant changes in baseline were shown in creatinine among the two groups or within either groups (P > 0.05).
Conclusion
The consumption of 500 mg/d symbiotic supplementation for 9 weeks could improve the HbA1c, BMI and Microalbuminuria in T2D. Although, No effect has been indicated on FBS, lipid profiles, urea and creatinine.
Trial Registration
The trial has been registered in the Iranian Registry of Clinical Trials
IRCT2015072223284N1
, identifier. Registered 21 May 2016 “retrospectively registered”.</abstract><cop>London</cop><pub>BioMed Central</pub><pmid>28589103</pmid><doi>10.1186/s40200-017-0304-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2251-6581 |
| ispartof | Journal of diabetes and metabolic disorders, 2017-06, Vol.16 (1), p.23-23, Article 23 |
| issn | 2251-6581 2251-6581 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5457616 |
| source | SpringerNature Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Blood glucose Cardiovascular diseases Care and treatment Clinical trials Complications and side effects Diabetes Diet Double-blind studies Endocrinology Health aspects Hormones Inflammation Insulin resistance Lipids Medicine Medicine & Public Health Metabolic Diseases Metabolism Mortality Nutrition research Oxidative stress Peptides Permeability Prebiotics Probiotics Research Article Risk factors Rodents Studies Type 2 diabetes |
| title | Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A52%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20symbiotic%20supplementation%20on%20glycemic%20control,%20lipid%20profiles%20and%20microalbuminuria%20in%20patients%20with%20non-obese%20type%202%20diabetes:%20a%20randomized,%20double-blind,%20clinical%20trial&rft.jtitle=Journal%20of%20diabetes%20and%20metabolic%20disorders&rft.au=Ebrahimi,%20Zarin%20sadat&rft.date=2017-06-02&rft.volume=16&rft.issue=1&rft.spage=23&rft.epage=23&rft.pages=23-23&rft.artnum=23&rft.issn=2251-6581&rft.eissn=2251-6581&rft_id=info:doi/10.1186/s40200-017-0304-8&rft_dat=%3Cgale_pubme%3EA507275165%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1905584915&rft_id=info:pmid/28589103&rft_galeid=A507275165&rfr_iscdi=true |